Polymyalgia Rheumatica and Giant Cell Arteritis: Why New Headache or Jaw Pain Is Urgent

Margaret had lived with polymyalgia rheumatica for eight months. The shoulder stiffness that once turned brushing her hair into a two-handed project had eased, her treatment was being tapered, and mornings felt ordinary again. Then, over a single weekend, a dull ache settled behind her left temple. Halfway through a bagel, her jaw grew so tired she had to stop chewing. She put it down to tension.

Her story is a composite, but the pattern is one rheumatologists recognize on sight, and it is the reason the polymyalgia rheumatica giant cell arteritis warning appears on so many patient leaflets. The two conditions travel together. One is painful and disruptive. The other can take a person’s eyesight in the space of a few days, and it rarely gives it back.

This explainer covers what links the two, which symptoms shift the clock from weeks to hours, and what usually happens once you pick up the phone.

What is the polymyalgia rheumatica giant cell arteritis warning, and why do doctors repeat it?

Polymyalgia rheumatica, usually shortened to PMR, is an inflammatory condition that causes aching and stiffness across the shoulders, neck and hips. Giant cell arteritis, or GCA, is a vasculitis, meaning inflammation of blood vessel walls, and it targets medium and large arteries, especially the branches that climb the side of the head and the vessels that feed the eye. On paper they look like different diseases. In clinic they behave like siblings.

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) estimates that roughly 15% of people with PMR go on to develop GCA, and that about half of people with GCA also have PMR-type aching. Both cluster in the same age group, share the same inflammatory blood-test pattern, and respond to the same class of medicine. Many rheumatologists now describe them as two expressions of one underlying process rather than two unrelated diagnoses.

That overlap is the entire point of the warning. A person living with PMR already has an immune system primed for this kind of inflammation, so a new symptom above the neck should never be filed under getting older. The stakes are lopsided. PMR that waits a week for a routine appointment loses very little. GCA that waits a week can permanently damage the optic nerve, and once vision is lost to GCA it very rarely returns.

Clinicians repeat the warning because the disease usually gives notice. Damage from blocked blood flow, which doctors call ischemia, tends to follow headache and jaw symptoms rather than arrive unannounced. There is nearly always a window. The rest of this article is about recognizing that window and acting inside it.

What is the first symptom of polymyalgia rheumatica?

Ask a room of people with PMR what they noticed first and most will describe the same morning. They woke unable to lift their arms to pull on a shirt, or they had to roll sideways and push up from the mattress because their hips would not cooperate. The stiffness is bilateral, meaning it affects both sides, and it concentrates in the shoulders and upper arms, the neck, and the hips and thighs. Hands and feet are usually spared.

Three features separate it from ordinary wear and tear. Speed comes first: many people go from feeling well to markedly limited over days to a couple of weeks, sometimes seemingly overnight. Timing comes second: the stiffness is worst on waking and after sitting still, and the NHS notes it commonly lasts well beyond half an hour before easing. The third feature is the whole-body signal. Low-grade fever, fatigue, loss of appetite, unintended weight loss and a flat, unwell feeling frequently ride along with the stiffness.

The pain of PMR comes from inflammation of the bursae, the fluid-filled cushions around joints, and of the joint linings at the shoulder and hip girdles. It is not a disease of the muscle fibers, even though it feels muscular. Strength tests are typically normal; the problem is pain-limited movement, not weakness. That distinction matters, because true weakness points toward other conditions a clinician will want to exclude.

PMR on its own is rarely dangerous. What makes its first symptom worth prompt attention is the company it keeps. Anyone over 50 with new, rapid-onset shoulder and hip stiffness should expect to be asked, at every visit, about headaches, scalp tenderness, jaw symptoms and vision. The first symptom of PMR is a stiff morning. The first symptom that must never be ignored is what the next sections describe.

What is the first symptom of giant cell arteritis?

Headache is the most common opening move, and it is a particular kind of headache. It is new, or clearly different from any headache the person has known before. It tends to sit over one or both temples, though it can settle anywhere on the scalp, and people describe it as persistent and boring rather than throbbing. Over-the-counter pain relievers that usually tame a tension headache tend to make little difference. Mayo Clinic lists this new, persistent head pain as the most frequent symptom.

Scalp tenderness follows closely. People notice it when brushing their hair, resting their head on a pillow or putting on glasses; the skin over the temple feels sore, and the temporal artery itself may feel thickened, cord-like or tender under the fingertips. Some people can no longer feel a pulse in it.

Next come symptoms that reflect blood struggling through narrowed arteries. Jaw pain or fatigue while chewing, covered in its own section below, is one. Tongue pain during eating is a rarer cousin. Visual symptoms are the ones every clinician fears: brief episodes of blurring or dimming, double vision, a curtain or shadow across part of one eye, or sudden painless loss of sight in one eye. These may be transient at first, lasting minutes, before becoming permanent.

Not everyone follows this script. A meaningful minority present with only fever, fatigue, weight loss and a raised inflammatory blood marker, with no headache at all. Others report aching arms on use because the arteritis has settled in the vessels of the arm. The practical lesson is that the first symptom of giant cell arteritis is really the first new symptom in someone over 50 whose body is already inflamed, and the safe assumption is to have it checked the same day.

How giant cell arteritis works: what is actually happening in the artery

Arteries are not passive pipes. Their walls have three layers, and in GCA the immune system mistakes the inner and middle layers for something that must be attacked. Immune cells pour in, and some fuse into the oversized giant cells that give the disease its name. Clusters of these cells, called granulomas, form inside the wall. The wall thickens and swells inward, the channel narrows, and tissue downstream begins to run short of oxygen-rich blood.

The temporal arteries on either side of the forehead are favorite targets, which is why the older name temporal arteritis still circulates and why the headache sits where it does. Far more consequential are the small arteries that feed the optic nerve at the back of the eye. When those narrow enough, the nerve is starved and suffers what amounts to a stroke. Unlike skin or muscle, nerve tissue does not regenerate. That is why the vision loss of GCA is usually permanent, and why the window before it happens is the entire focus of care.

GCA can also involve the aorta, the body’s main artery, and its major branches. Inflammation there weakens the wall over time and can lead to an aortic aneurysm, a balloon-like widening that Mayo Clinic lists among the long-term complications, alongside stroke. This is the reason follow-up continues long after the headache has gone.

PMR shares the same immune over-activation but expresses it in the soft tissues around the shoulders and hips rather than in artery walls. Imaging studies show inflamed bursae and tendon sheaths rather than inflamed vessels. Nobody yet knows why one person’s immune system chooses the bursa and another’s chooses the artery. Age-related changes in immune regulation and in the vessel wall, genetic background and possible environmental triggers are all under active study, and none has been proven to be the cause.

Temporal arteritis jaw pain: why chewing that tires the jaw is a red flag

Jaw claudication is a term worth learning. Claudication means pain or fatigue in a muscle that appears with use and settles with rest, because the muscle is not receiving enough blood to keep working. Most people meet the word in the legs, where narrowed arteries cause calf pain on walking. In GCA it turns up in the jaw.

The experience is distinctive. The first few bites of a meal are fine. Then the muscles at the angle of the jaw begin to ache or feel exhausted, sometimes more on one side, and the person has to stop chewing and wait. Tough foods bring it on fastest: a bagel, a steak, a piece of gum. Talking at length can do the same thing. It is not the sharp, clicking pain of a jaw-joint problem, and it is not the constant throb of a dental abscess. It is a muscle running out of fuel.

Why does one symptom carry so much weight? Because it is a direct readout of arterial narrowing in the head, in the same vascular neighborhood that supplies the eye. When chewing muscles are ischemic, the vessels next door may not be far behind. Jaw claudication is one of the features written into formal classification criteria for GCA, and clinicians regard it as a marker of higher risk of visual complications. Guideline pathways therefore treat it as a trigger for urgent assessment rather than watchful waiting.

A practical caution belongs here. Dentists and physicians see jaw pain constantly, and most of it has ordinary causes. What separates GCA is the pattern with use, the age group, and the companions: new headache, scalp soreness, feeling generally unwell, or an existing diagnosis of PMR. When those line up, the jaw is not a dental problem until GCA has been considered and excluded.

Why can giant cell arteritis cause blindness, and how fast does it happen?

The eye has the least margin of any organ in this disease. The optic nerve receives its blood through a handful of small arteries branching from the ophthalmic artery, which itself belongs to the system GCA inflames. There is little redundancy in that supply. Narrow the wrong vessel and the front of the optic nerve infarcts, a process ophthalmologists call arteritic anterior ischemic optic neuropathy. The person typically notices sudden, painless loss of vision in one eye, often on waking.

What makes GCA uniquely time-sensitive is the sequence. Many people report warning episodes first: seconds or minutes of dimming, grayness or a shade drawn across part of the visual field, followed by recovery. These transient episodes mean blood flow is already marginal. Mayo Clinic describes vision loss as a serious and frequently irreversible complication of untreated disease, and notes that the second eye is also at risk if treatment is delayed.

Irreversible is the operative word. Steroid treatment started before vision is affected is the main means of preventing loss; started afterward, it is aimed at protecting the other eye and seldom restores what has gone. That is why GCA is one of the few rheumatology diagnoses that emergency departments are trained to treat first and confirm afterward, and why a clinician who suspects it may begin treatment before a biopsy or scan is arranged. Waiting for test results before starting is considered the wrong order of events.

Double vision, a drooping eyelid and pain on eye movement are less common but also reflect ischemia of the muscles and nerves around the eye. Stroke, particularly in the back of the brain, is a feared though less frequent event. None of these should be evaluated by phone or at a next-available appointment. Same-day, in-person assessment is the standard, and if a primary care office cannot see you that day, an emergency department can.

Who gets PMR and GCA, and who is usually asked to look for another explanation?

Both conditions are almost exclusively diseases of later life. NIAMS notes they rarely occur before age 50, and Mayo Clinic puts the peak for GCA between 70 and 80. Women are affected about twice as often as men, and people of Northern European, particularly Scandinavian, ancestry have the highest recorded rates, though both diagnoses occur in every population.

Who is the urgent pathway usually for? Anyone over 50 with a new headache plus any of scalp tenderness, jaw claudication, visual symptoms or an established PMR diagnosis. Anyone with unexplained fever, fatigue and weight loss alongside a markedly raised inflammatory blood marker. Anyone with PMR whose symptoms change character, or return during a taper together with head or eye symptoms. For these people the NHS advises urgent referral, and treatment may begin before the specialist visit takes place.

Who is usually asked to look elsewhere first? A person in their thirties with a tension-type headache and normal blood tests is not a GCA candidate; the diagnosis is so rare under 50 that clinicians will reasonably pursue other causes. Someone with symmetrical swelling of the small joints of the hands is more likely to have rheumatoid arthritis than PMR. Genuine muscle weakness rather than pain-limited movement steers toward muscle diseases. A headache unchanged for years does not fit. Being asked to wait, or to see a different specialist, in those situations is not dismissal. It is the correct application of who the disease actually affects.

A gray zone exists. Older adults with PMR-type stiffness and normal inflammatory markers, or with a new headache but no other features, may be reviewed closely rather than treated immediately. In that setting the treating team weighs the risk of missing GCA against the risks of steroid exposure, and the decision is made jointly with the patient rather than by a rule.

PMR vs GCA symptoms: a side-by-side table

Because the two conditions overlap so heavily, it helps to see where they part ways. The table is a recognition aid rather than a self-diagnosis tool; the same person can sit in both columns at once.

Feature	Polymyalgia rheumatica (PMR)	Giant cell arteritis (GCA)
Where the inflammation sits	Bursae and joint linings around shoulders and hips	Walls of medium and large arteries: head, neck, arms, aorta
Typical first complaint	Both shoulders and hips stiff and aching on waking	New headache, sore scalp, jaw fatigue when chewing
Vision	Not affected by PMR itself	Blurring, double vision or sudden loss; often permanent
Whole-body symptoms	Fatigue, low fever, weight loss common	Same, and sometimes the only feature
Usual blood findings	ESR and CRP raised	ESR and CRP raised, often markedly
Confirmatory test	None specific; pattern plus response to treatment	Temporal artery ultrasound or biopsy
Urgency	Prompt, within days	Same day
Treatment duration (NHS, Mayo Clinic)	Commonly 1 to 2 years, sometimes longer	Commonly 1 to 2 years, sometimes longer
Link to the other (NIAMS)	Roughly 15% develop GCA	About half also have PMR symptoms

Two rows deserve the most attention. The vision row explains the asymmetry in urgency: PMR hurts, GCA can blind. The confirmatory-test row explains a frustration many patients voice, which is that PMR is diagnosed largely on the story and the response to treatment, while GCA usually gets an imaging study or a small operation to confirm it. That difference is deliberate. Because GCA is treated more intensively and for longer, clinicians want firmer proof before committing someone to that path.

Notice too what the two columns share. The blood pattern is the same, the age group is the same, the treatment class is the same, and the timeline is the same. When people with PMR are told to watch for headache, this table is why: a new entry in the right-hand column can appear at any point, including during a taper that seemed to be going well.

How are polymyalgia rheumatica and giant cell arteritis diagnosed?

Neither condition has a single defining test, which frustrates patients and clinicians alike. The diagnosis is assembled from age, the story, physical examination and a few key investigations.

Blood tests come first. The erythrocyte sedimentation rate, or ESR, measures how quickly red cells settle in a tube, and it rises when inflammatory proteins are present. C-reactive protein, or CRP, is a protein the liver releases in response to inflammation. Both are usually raised, often strikingly so, in active PMR and GCA. A full blood count may show mild anemia and a raised platelet count. Normal results do not fully exclude either disease, particularly GCA, but they do make it less likely.

For PMR, blood tests plus the classic pattern are often enough once look-alikes have been excluded. Clinicians typically check thyroid function, muscle enzymes, kidney and liver tests and sometimes rheumatoid arthritis markers, because several conditions imitate PMR. A brisk response to treatment is itself supporting evidence.

For GCA, confirmation matters more. Two tools dominate. Ultrasound of the temporal arteries at the temple and the axillary arteries under the arm can reveal a dark ring of wall swelling known as the halo sign; it is quick, painless and increasingly used as the first test. Temporal artery biopsy remains the traditional standard. Under local anesthetic, a short segment of the artery is removed through a small incision near the hairline and examined under a microscope for giant cells and inflammation. The NHS describes it as a small operation done under local anesthetic. A negative biopsy does not always rule GCA out, because inflammation can skip segments of the vessel.

Crucially, none of this delays treatment when suspicion is high. Steroids begun a few days before a biopsy do not usually erase the microscopic findings, so the accepted sequence is treat, then confirm. An eye examination by an ophthalmologist is arranged promptly whenever any visual symptom has occurred.

How are PMR and GCA treated, and why timing matters more than the exact medicine

The cornerstone of treatment for both conditions is a glucocorticoid, the medical name for the steroid class that mimics cortisol, the body’s own anti-inflammatory hormone. Glucocorticoids switch off the genes that drive inflammation across many immune cells at once, which is why they work so quickly and so broadly. The prescribing clinician chooses the starting intensity, the route and the taper, and those choices differ sharply between the two conditions. GCA is treated far more intensively, because the goal is protecting the eye rather than easing stiffness.

Speed of response is one of the clinical hallmarks. The NHS notes that PMR symptoms usually improve within a few days of starting treatment; when they do not, the diagnosis is revisited. Headache in GCA also tends to settle quickly, though any vision already lost typically does not recover.

What follows is a long, gradual reduction. The NHS and Mayo Clinic both describe treatment commonly continuing for one to two years, sometimes longer, with the treatment lowered in steps while symptoms and blood markers are watched. Flares during the taper are common and are managed by the treating team, never by a patient adjusting their own medicine.

Prolonged steroid exposure takes a toll on the body. Mayo Clinic lists bone thinning, raised blood sugar, raised blood pressure, weight gain, cataracts, thinning skin, mood change and increased infection risk. Clinicians usually pair treatment with protective measures: bone-density monitoring and bone-protecting medicine, blood pressure and glucose checks, and eye examinations. For GCA in particular, specialists may consider adding a medicine that blocks interleukin-6, a signaling protein central to this inflammation, with the aim of reducing the total steroid a person needs. A conventional immune-modulating drug is sometimes used for the same purpose in relapsing PMR. Whether either is appropriate, and when, is an individual decision for the specialist team, weighed against each person’s other conditions and risks.

What the first days and weeks after diagnosis usually look like

Day one often moves fast. When GCA is suspected, treatment typically starts the same day, and ultrasound or biopsy is arranged over the following days. An eye examination is booked promptly if any visual symptom has occurred. For PMR alone the pace is calmer: blood tests, a treatment start, and a review within the following week or two.

Inside the first week, most people with either condition notice real change. Headaches ease, the scalp stops hurting, chewing becomes ordinary again, and the morning stiffness of PMR loosens enough that dressing is no longer a project. The transformation can feel almost suspicious. It is expected, and it is one reason clinicians ask people to keep a simple symptom diary, because the pattern of improvement, and of any return, guides everything that follows.

The first month brings a repeat blood test, a conversation about side effects, and often the first small step down in treatment. Disturbed sleep, increased appetite and a restless, jittery feeling are common early steroid effects. They generally lessen as treatment is reduced, but they deserve mention to the team rather than silent endurance.

Months two through twelve are the long middle. Appointments space out, blood tests continue at intervals the team sets, and the taper proceeds in cautious steps. This is when flares tend to happen: returning stiffness, a rising inflammatory marker, or, in GCA, a returning headache. The NHS notes that symptoms coming back during dose reduction is common in PMR. Flares are not failures. They are information, and the team adjusts the plan accordingly.

Beyond a year, many people are on low levels of treatment or none, though the NHS notes some need it for longer. For anyone who has had GCA, long-term follow-up usually includes attention to the aorta, because Mayo Clinic lists aneurysm as a possible late complication that develops silently.

What people often get wrong about polymyalgia rheumatica and giant cell arteritis

Some misunderstandings about these conditions are harmless. Several are not, and they show up repeatedly in clinic conversations.

• It is a muscle disease. The pain of PMR is felt in the muscles but arises from inflamed bursae and joint linings. Strength is normal, and PMR is not fibromyalgia, chronic fatigue syndrome or simple aging. Mislabeling it delays the right questions about GCA.
• GCA always means a headache at the temple. Headache is the most common feature, but a minority present with fever, weight loss and fatigue alone, and some with arm pain on use. A raised inflammatory marker in an unwell older adult keeps GCA on the list even without head pain.
• A normal ESR rules it out. Usually raised, not always. Clinicians rely on the whole picture, and a normal result in someone with jaw claudication and visual symptoms does not end the conversation.
• A negative biopsy settles it. Inflammation can skip segments of the artery, so a clear biopsy in a person with a convincing story may still be treated as GCA.
• Once vision returns after a brief episode, the danger has passed. Transient dimming is a warning that flow is marginal, not reassurance. It is among the strongest reasons for same-day care.
• Steroids will restore lost sight. Started early, they protect vision. Started after loss, they mostly protect the other eye.
• Feeling well means it is safe to stop. Long-term steroids suppress the body’s own cortisol production, and abrupt withdrawal can be dangerous. Any change belongs with the prescriber.
• Jaw pain in an older adult is a dental matter. Often it is. When it builds with chewing and eases with rest, GCA has to be considered first.

Underneath most of these myths sits a single error: treating GCA like a diagnosis that can be confirmed at leisure. It is closer to a stroke in its logic. Suspicion alone triggers action, and certainty comes second.

Questions to ask your care team

A diagnosis of PMR or GCA usually arrives quickly, and treatment may begin before there is time to think. Bring these questions to the first unhurried appointment, or to the next phone call, so that the plan is yours as well as the team’s.

• Do I have PMR, GCA or both, and how confident are you in that at this stage?
• Which of my symptoms would you consider a same-day emergency, and where exactly should I go if they occur outside office hours?
• Will I have an ultrasound, a biopsy or both, and does the timing of those tests change my treatment?
• Should I see an ophthalmologist now, even though my vision feels normal?
• How will you decide when and how quickly to reduce my treatment, and what signs would make you pause?
• What steroid side effects should I watch for, and which of them need a call rather than a mention at the next visit?
• Will my bone density, blood pressure and blood sugar be checked, and how often?
• Is a steroid-sparing medicine something you would consider for me, and what would make it appropriate or inappropriate?
• If I have PMR only, what exactly should I watch for that would suggest GCA is developing?
• Who do I contact between appointments, and how quickly should I expect a reply?
• How will my other conditions and current medicines interact with this treatment plan?
• What follow-up will I need after the treatment ends, particularly for the aorta if I have had GCA?

Write the answers down. Several of them, especially the emergency instructions and the contact route, are worth pinning to the refrigerator. Treatment for these conditions stretches over many months, and the people who fare best are usually those who know exactly which symptom warrants which response, and who never have to guess whether to call.

When to call your doctor: polymyalgia rheumatica giant cell arteritis warning signs

Seek same-day care, through your doctor’s office or an emergency department, if you are over 50, and especially if you have PMR, and you notice any new headache or a headache unlike your usual ones, tenderness of the scalp or temples, jaw pain or fatigue that builds while chewing, or any change in vision at all, including brief episodes that resolved. Sudden loss of sight in one eye, double vision, or a curtain across part of your visual field is an emergency: go directly to an emergency department rather than waiting for a call back. These are the red flags for giant cell arteritis, and the standard is assessment within hours, not days.

Also call promptly, though not necessarily to an emergency department, if you experience:

• New or worsening shoulder and hip stiffness that lasts more than half an hour each morning in someone over 50, particularly with fatigue, low fever or unexplained weight loss.
• Return of PMR or GCA symptoms during a taper, or a rising inflammatory marker your team has asked you to report.
• Fever, cough, painful urination or any sign of infection while on steroids, since steroids blunt the immune response and can mask how unwell you are.
• Persistent nausea or vomiting that prevents you from taking your prescribed medicine, because missed steroid treatment can be dangerous when the body’s own cortisol production is suppressed.
• New chest, back or abdominal pain, or a pulsing sensation in the abdomen, in anyone with a history of GCA, given the possibility of aortic involvement.
• Marked mood change, severe sleeplessness, excessive thirst or frequent urination, or new visual clouding, which may reflect steroid effects that need review.

None of this is a self-diagnosis checklist. It is a map of the moments when a phone call is the right decision. The treating team decides what the symptom means and what, if anything, changes in the plan. Your job is only to make the call early, and to make it without apology. In this pair of conditions, the person who rings too soon has never once been the problem.

Frequently asked questions

What are the red flags for polymyalgia rheumatica?

The red flags in someone with polymyalgia rheumatica are new symptoms above the neck: a new or different headache, scalp or temple tenderness, jaw pain or fatigue while chewing, and any visual disturbance, including brief episodes. These suggest giant cell arteritis, which NIAMS estimates develops in roughly 15% of people with PMR, and they require same-day assessment. Fever, weight loss or stiffness returning during a taper also warrant a prompt call to the treating team.

What is the first symptom of giant cell arteritis?

A new, persistent headache is the most common first symptom, usually over one or both temples and unlike previous headaches, according to Mayo Clinic. Scalp tenderness, jaw pain when chewing and visual changes often follow. Some people instead notice only fever, fatigue and weight loss. In anyone over 50, a new headache with any of these companions is treated as urgent until GCA has been excluded.

What is the first symptom of polymyalgia rheumatica?

The first symptom is usually sudden stiffness and aching across both shoulders and often the hips, worst on waking and after sitting still, and lasting more than half an hour, as the NHS describes. Many people go from well to markedly limited within days. Fatigue, low-grade fever and reduced appetite frequently accompany it. Strength is typically normal; movement is limited by pain rather than weakness.

What are the red flags for giant cell arteritis?

The red flags are new headache in someone over 50, scalp or temple tenderness, jaw pain or fatigue that builds while chewing, and any visual symptom, including transient dimming, double vision or a shadow across part of the field. Sudden painless loss of sight in one eye is an emergency. Mayo Clinic describes vision loss as a frequently irreversible complication of delayed treatment, so these signs call for same-day, in-person assessment.

Can you have giant cell arteritis without a headache?

Yes. Although headache is the most common feature, a minority of people present with only fever, fatigue, weight loss and raised inflammatory blood markers, or with aching arms during use when the arteries of the arms are involved. This silent form is one reason clinicians keep GCA on the list for any unwell older adult with unexplained inflammation, and why ultrasound of the arm arteries is sometimes part of the assessment.

How quickly can giant cell arteritis cause blindness?

Vision can be lost suddenly, often over hours, and once lost it rarely returns. Many people have brief warning episodes of dimming or blurring in the days beforehand. Mayo Clinic notes that without prompt treatment the second eye is also at risk. This is why treatment usually begins as soon as GCA is suspected, before ultrasound or biopsy confirms it, rather than after.

Does polymyalgia rheumatica always turn into giant cell arteritis?

No. NIAMS estimates that roughly 15% of people with polymyalgia rheumatica develop giant cell arteritis, which means most never do. The overlap is large enough, however, that everyone with PMR is asked to watch for new headache, scalp tenderness, jaw symptoms and visual change for as long as the condition is active, including during treatment tapers when the risk of a flare is higher.

Is temporal arteritis the same as giant cell arteritis?

Yes. Temporal arteritis is the older name, chosen because the temporal arteries at the side of the head are so often involved. Giant cell arteritis is now preferred because the disease also affects the aorta and its branches, including the arteries of the arms, and because the giant cells seen under the microscope define it. The NHS and Mayo Clinic use the two names interchangeably.

Can giant cell arteritis come back after treatment?

It can. Flares are common while treatment is being reduced, and the NHS notes that returning symptoms during dose reduction is frequent in the related condition PMR as well. A returning headache, scalp tenderness, jaw symptom or visual change during or after a taper should be reported the same day. Long-term follow-up also monitors for late aortic complications, which Mayo Clinic lists among the possible outcomes.

Should I stop my steroids if I feel better?

Steroids should not be stopped or changed without your prescriber’s guidance. Feeling well within days is the expected response, not a sign the disease has gone. Long-term steroid treatment also suppresses the body’s own cortisol production, and abrupt withdrawal can be dangerous. The NHS and Mayo Clinic describe treatment commonly lasting one to two years with a gradual, supervised taper, and every adjustment is a decision for the treating team.

References

• Polymyalgia Rheumatica and Giant Cell Arteritis: NIAMS, National Institutes of Health
• Polymyalgia rheumatica: NHS
• Temporal arteritis: NHS

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.